Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00885820 · ClinicalTrials.gov registry record · Phase 4
Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection
A Phase 4 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 240
- Enrollment target
NCT00885820: Completed Phase 4 study, sponsored by Astellas Pharma.
NCT00885820 is a Phase 4 study that has completed, run by Astellas Pharma. The registered enrollment target is 240 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00885820, a Phase 4 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 240 participants
- Enrollment target
Study Summary
This multicentre randomized, controlled trial (RCT) compared renal allograft histology and function in subjects treated with Tacrolimus + MMF + prednisone undergoing early protocol biopsies and treatment of subclinical rejection versus a non-protocol biopsy control group.
Interventions
- DRUG Tacrolimus
- DRUG MMF
- DRUG Corticosteroids (Prednisone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2001-09 |
| Est. Completion | 2006-01 |
| Phase | Phase 4 |
What the finished NCT00885820 record still lists
NCT00885820 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (54% lower).
The record links to 0 conditions, and to 3 interventions - of which Tacrolimus is the first listed.
NCT00885820 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00885820 about?
NCT00885820 is a clinical study titled "Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection". This multicentre randomized, controlled trial (RCT) compared renal allograft histology and function in subjects treated with Tacrolimus + MMF + prednisone undergoing early protocol biopsies and treatment of subclinical rejection versus a non-protocol biopsy control group.
What is the current status of trial NCT00885820?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 240 participants. The study started on 2001-09. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00885820?
The interventions under investigation include: Tacrolimus (DRUG), MMF (DRUG), Corticosteroids (Prednisone) (DRUG).
Who is sponsoring clinical trial NCT00885820?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00885820's enrollment target sits among peer trials
240 360th of 2000 higher than 1,635 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia